Journal
BREAST CANCER RESEARCH
Volume 9, Issue 1, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/bcr1634
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA064277, R01CA090899] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA090899, R01 CA064277, R01CA64277, R01CA90899] Funding Source: Medline
Ask authors/readers for more resources
Introduction Most previous studies have focused on evaluating the association between circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and breast cancer risk. Emerging evidence over the past few years suggests that IGFBP-3 may act directly on mammary epithelial cells. Methods To understand the role of IGFBP-3 in breast tumorigenesis, we investigated IGFBP3 mRNA expression levels in benign and malignant breast tumors and their adjacent normal tissues using real-time quantitative PCR. Results Cancer tissues had significantly lower IGFBP3 expression than benign tumor tissues ( p < 0.001). IGFBP3 expressions in both tumor and adjacent tissues were higher in patients who had proliferative benign tumors than in those who had non-proliferative benign tumors. Among patients with benign breast disease, IGFBP3 expression in the tumor was significantly higher than that in their adjacent normal tissue. There were no apparent associations of IGFBP3 expression in cancer tissues with either overall survival or disease-free survival in a cohort of 521 patients with breast cancer. Conclusion Our findings suggest that the expression level of IGFBP3 in breast tissues may be involved in breast tumorigenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available